Us Congress 2025-2026 Regular Session

Us Congress House Bill HB2483

Introduced
3/31/25  

Caption

SUPPORT for Patients and Communities Reauthorization Act of 2025

Impact

The bill's initiatives would significantly influence state laws by providing additional funds and frameworks for community-based recovery programs, residential treatment options for pregnant and postpartum women, and access to addiction medicine providers. One of its notable features is the emphasis on tailored approaches to different communities, recognizing that local needs may vary. Additionally, it promotes state choice in managing prescription drug monitoring programs, thus allowing states greater flexibility in addressing substance use challenges that are specific to their populations.

Summary

House Bill 2483, titled the ‘SUPPORT for Patients and Communities Reauthorization Act of 2025,’ aims to reauthorize several programs that address opioid use disorder prevention, treatment, and recovery services. It builds upon previous legislation that sought to combat the national opioid epidemic by enhancing funding, improving access to treatment for individuals with substance use disorders, and reinforcing the support systems in place for families affected by such disorders. The bill proposes a comprehensive approach that spans various aspects of prevention, treatment, and recovery, including prenatal and postnatal health services.

Contention

While the overall intent of HB 2483 is widely supported among legislators, points of contention include the adequacy of funding proposed for these programs and fears that the funds may not reach the most affected communities effectively. Critics caution that without careful oversight, the increased funding could lead to inefficiencies or misallocation of resources, undermining the effectiveness of the programs designed to combat the opioid crisis. Moreover, there are ongoing debates about balancing federal and state responsibilities in administering substance use treatment programs to address the crisis adequately.

Congress_id

119-HR-2483

Policy_area

Health

Introduced_date

2025-03-31

Companion Bills

US HB912

Related bill 9–8–8 Lifeline Cybersecurity Responsibility Act

US SB500

Related bill CAREER Act of 2025 Comprehensive Addiction Recovery through Effective Employment and Reentry Act of 2025

US SB891

Related bill Bipartisan Health Care Act Pandemic and All-Hazards Preparedness and Response Act SUPPORT for Patients and Communities Reauthorization Act of 2025

US SB946

Related bill MATE Improvement Act Medication Access and Training Expansion Improvement Act

Similar Bills

US HB27

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl ActThis bill permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.Under the bill, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term).Additionally, the bill establishes a new, alternative registration process for certain schedule I research.The bill also makes several other changes to registration requirements for conducting research with controlled substances, includingpermitting a single registration for related research sites in certain circumstances,waiving the requirement for a new inspection in certain situations, andallowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.Finally, the bill expresses the sense that Congress agrees with the interpretation of Controlled Substances Act in United States v. McCray, a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.

US SB665

Fatal Overdose Reduction Act of 2025

US SB331

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl ActThis bill permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.Under the bill, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term).Additionally, the bill establishes a new, alternative registration process for certain schedule I research.The bill also makes several other changes to registration requirements for conducting research with controlled substances, includingpermitting a single registration for related research sites in certain circumstances,waiving the requirement for a new inspection in certain situations, andallowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.Finally, the bill expresses the sense that Congress agrees with the interpretation of the Controlled Substances Act in United States v. McCray, a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.

US HB2281

Strengthening Job Corps Act of 2025

US SB860

BUST FENTANYL Act Break Up Suspicious Transactions of Fentanyl Act

US SB91

Western Wildfire Support Act of 2025

US HB440

READY Accounts ActThis bill establishes a new Residential Emergency Asset-accumulation Deferred Taxation Yield (READY) account, allows individuals to make tax-deductible contributions of up to $4,500 per year to such accounts (adjusted annually for inflation), and allows individuals to take tax-free distributions from such accounts to pay for qualified home disaster mitigation and recovery expenses related to a principal residence owned by the taxpayer.Under the bill, qualified home disaster mitigation expenses include expenses certified by a qualified industry professional as meeting criteria to mitigate damage from a natural or other disaster, includinginstalling a roofing underlayment to sheathing, impact-resistant windows, impact-resistant entry doors, or ground anchors;replacing a roof covering;applying a foam adhesive to reinforce the roof structure;strengthening the connection of the roof deck to roof framing, roof-to-wall connections, soffits, or attic ventilation openings;elevating a residence; orachieving the current building code standard.Qualified home disaster recovery expenses include costs for repairing damage to a residence resulting from fire, storm, or other casualty (provided such costs are not reimbursed).Distributions from a READY account used for anything other than qualified home disaster mitigation and recovery expenses must be included in gross income and are subject to a 20% penalty. (Some exceptions apply.)Finally, the bill imposes a 6% tax on contributions in excess of the annual limit. (Some exceptions apply.) 

US HB1471

VA Appeals Reform Act of 2025